| Title |
Clinical utility of ustekinumab in Crohn’s disease
|
|---|---|
| Published in |
Journal of Inflammation Research, February 2018
|
| DOI | 10.2147/jir.s157358 |
| Pubmed ID | |
| Authors |
Paulo Gustavo Kotze, Christopher Ma, Abdulelah Almutairdi, Remo Panaccione |
| Abstract |
The introduction of anti-tumor necrosis factor (TNF) therapy marked an important milestone in the management of moderate-to-severe Crohn's disease (CD). However, there remains a pressing demand for alternative therapeutic options for patients with primary nonresponse, secondary loss of response, or intolerable side effects to conventional treatment and TNF antagonists. Ustekinumab (UST) is a fully human IgG1κ monoclonal antibody that inhibits the p40 subunit shared by the proinflammatory cytokines, the interleukin (IL)-12 and -23. This blockade leads to dampening of the inflammatory cascade and differentiation of inflammatory T cells. The clinical development program for UST in CD includes dose finding Phase II (Crohn's Evaluation of Response to Ustekinumab Anti-Interleukin-12/23 for Induction [CERTIFI]) and the pivotal Phase III (UNITI) trials that demonstrated both the clinical efficacy and safety in anti-TNF-naive and anti-TNF-exposed patients. Real-world evidence has further defined the role of UST in CD management. In this review, we discuss the mechanism of action of UST, describe the results of the randomized controlled trials with this agent, and review the real-world efficacy and safety data from observational cohorts. Finally, we identify areas of future research in the IL-12/23 inflammatory pathway and discuss the positioning of this novel therapeutic option in CD treatment algorithms. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Saudi Arabia | 2 | 50% |
| United States | 1 | 25% |
| Brazil | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 50% |
| Practitioners (doctors, other healthcare professionals) | 2 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 116 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 116 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 16 | 14% |
| Researcher | 15 | 13% |
| Student > Bachelor | 12 | 10% |
| Other | 11 | 9% |
| Student > Postgraduate | 7 | 6% |
| Other | 21 | 18% |
| Unknown | 34 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 42 | 36% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 8% |
| Biochemistry, Genetics and Molecular Biology | 8 | 7% |
| Agricultural and Biological Sciences | 5 | 4% |
| Nursing and Health Professions | 3 | 3% |
| Other | 14 | 12% |
| Unknown | 35 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 February 2018.
All research outputs
#13,003,571
of 23,020,670 outputs
Outputs from Journal of Inflammation Research
#190
of 803 outputs
Outputs of similar age
#205,276
of 440,112 outputs
Outputs of similar age from Journal of Inflammation Research
#5
of 11 outputs
Altmetric has tracked 23,020,670 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 803 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 440,112 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.